title: Value of resection of pulmonary metastases in head and neck cancer patients.
abstract: BACKGROUND
  Literature shows no data about a complete cohort of head and neck cancer patients who developed pulmonary metastases. In this study, we investigate factors related to survival, with emphasis on the role of a pulmonary metastasectomy.
  
  
  METHODS
  A retrospective review of 138 patients who developed pulmonary metastases (5.5% of all head and neck cancer patients) in the period 1978 to 1994 is presented. In a stepwise regression analysis (Cox), factors were identified related to survival. Also investigated was whether the prognostic value of potential prognosticators differed between the group that underwent metastasectomy and the group that did not.
  
  
  RESULTS
  One hundred thirty-eight patients had metastases originating from head and neck cancer. The 5-year survival rate for all these patients was 13%. Younger patients (P = .011), patients with a longer disease-free interval (DFI) (P = .011), patients with a longer disease-free interval (DFI) (P = .016), and patients with a nonsquamous cell carcinoma (P = .038) did better. No evidence of a relationship between survival and sex or survival and number of metastases was found. Twenty-one patients underwent surgical resection of their pulmonary metastases. In 18 patients the resection was complete. The 5-year survival rate for patients who underwent a metastasectomy was 59%, compared with 4% in the nonmetastasectomy group (P = .0033).
  
  
  CONCLUSIONS
  Isolated pulmonary metastases from head and neck cancer are potentially curable by surgical resection. Preconditions for this approach are locoregional control of the primary lesion and technical resectability of the pulmonary metastases. Patients with a long interval between primary treatment and the diagnosis of pulmonary metastases may benefit more from resection therapy.
authors.affiliation: Department of Otolaryngology--Head & Neck surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
authors.forename: J
authors.initials: J
authors.lastname: Wedman
authors.forename: A J
authors.initials: AJ
authors.lastname: Balm
authors.forename: A A
authors.initials: AA
authors.lastname: Hart
authors.forename: B M
authors.initials: BM
authors.lastname: Loftus
authors.forename: F J
authors.initials: FJ
authors.lastname: Hilgers
authors.forename: R T
authors.initials: RT
authors.lastname: Gregor
authors.forename: N
authors.initials: N
authors.lastname: van Zandwijk
authors.forename: F A
authors.initials: FA
authors.lastname: Zoetmulder
mesh_terms: D000368:Aged; D002277:Carcinoma / Q000401:mortality / Q000473:pathology / Q000556:secondary* / Q000601:surgery*; D002294:Carcinoma, Squamous Cell / Q000473:pathology; D005260:Female; D006258:Head and Neck Neoplasms / Q000473:pathology*; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome